Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.

Deniz Can Guven; Nicolas Sayegh; Nishita Tripathi; Mustafa Erman; Neeraj Agarwal; Umang Swami

Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.

Deniz Can Guven
, Nicolas Sayegh
, Nishita Tripathi
, Mustafa Erman
, Neeraj Agarwal
, Umang Swami

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	40
Issue number	16
Publication status	Published - 1 Jun 2022
Event	Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Duration: 3 Jun 2022 → 7 Jun 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{870ccae246f64ed1bfc6e0c67cd5d2fc,

title = "Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.",

author = "Guven, \{Deniz Can\} and Nicolas Sayegh and Nishita Tripathi and Mustafa Erman and Neeraj Agarwal and Umang Swami",

year = "2022",

month = jun,

day = "1",

language = "English",

volume = "40",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "16",

note = "Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) ; Conference date: 03-06-2022 Through 07-06-2022",

}

Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis. / Guven, Deniz Can; Sayegh, Nicolas; Tripathi, Nishita et al.
In: Journal of Clinical Oncology, Vol. 40, No. 16, 01.06.2022.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs)

T2 - Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

AU - Guven, Deniz Can

AU - Sayegh, Nicolas

AU - Tripathi, Nishita

AU - Erman, Mustafa

AU - Agarwal, Neeraj

AU - Swami, Umang

PY - 2022/6/1

Y1 - 2022/6/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=performanshacettepe&SrcAuth=WosAPI&KeyUT=WOS:000863680301500&DestLinkType=FullRecord&DestApp=WOS_CPL

M3 - Meeting Abstract

SN - 0732-183X

VL - 40

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

Y2 - 3 June 2022 through 7 June 2022

ER -

Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.

UN SDGs

Other files and links

Cite this